Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297776 | 0.88 | CA1 (0.52) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16913946 | 0.85 | PIK3C3 (0.41) | CA1CA2CA9CA12CA3 | |
| SCHEMBL29556988 | 0.85 | PIK3CA (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1557904 | 0.85 | PIK3CA (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL109782 | 0.83 | ALPL (0.52) | ALPLPIK3CA | |
| SCHEMBL9955288 | 0.82 | PIK3CG (0.52) | ALPLPDGFRBKDRPIK3CA | |
| SCHEMBL13034959 | 0.82 | PIK3C3 (0.35) | PIK3C3PIK3CA | |
| SCHEMBL2067368 | 0.81 | GSK3A (0.38) | CA1CA2CA9CA12CA3 | |
| SCHEMBL17946272 | 0.80 | ALPL (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL22447413 | 0.80 | ALPL (0.39) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237073-A1 | Novel Polymorphs and Salts | GLAXO GROUP LTD (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9353098-B2 | Polymorphs and salts | GLAXO GROUP LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20150299177-A1 | Novel Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-9102668-B2 | Polymorphs and salts | GLAXO GROUP LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20140256721-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-8735390-B2 | Polymorphs and salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-05-27 | — | — | US | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20130165441-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165441-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | CA1 3614/4885CA2 977/4885CA9 3274/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | CA1 3419/4885CA2 3382/4885CA9 2400/4885 |
| US-20160237073-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | CA1 3614/4885CA2 977/4885CA9 3274/4885 |
| US-20150299177-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | CA1 3614/4885CA2 977/4885CA9 3274/4885 |
| US-20140256721-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | CA1 3614/4885CA2 977/4885CA9 3274/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | CA1 4388/4885CA2 2221/4885CA9 4728/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | CA1 4388/4885CA2 2221/4885CA9 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.